A.E. Babushkina
Research Subjects
Research Interests
A.E. Babushkina has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Korchagina
All-Russian Research Veterinary Institute of Pathology, Pharmacology and Therapy
1 shared publication - G.N. Bliznetsova1 shared publication
- I. V. Bryukhova
All-Russian Veterinary Research Institute of Pathology, Pharmacology and Therapy
1 shared publication - Liliya V. Cheskidova
All-Russian Research Veterinary Institute of Pathology, Pharmacology and Therapy
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Vitebsk State Academy of Veterinary Medicine in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
- Vol. 60 (4)
TOXICITY PARAMETERS OF A COMPLEX ANTIMICROBIAL DRUG BASED ON LEVOFLOXACIN USED ON WHITE MICE
The article presents the results of a study of the acute toxicity of a new antimicrobial drug based on levofloxacin. The trial was conducted on white laboratory mice, which were administered the drug under investigation once at different doses intragastrically and subcutaneously. As a result of the study, toxicity parameters were established, which made it possible to classify the new drug as Hazard class 4. The LD50 for subcutaneous administration for white mice was 13126.57±1537.49 mg/kg.
- 1 January 2024
- Published by Vitebsk State Academy of Veterinary Medicine in Transactions of the educational establishment “Vitebsk the Order of “the Badge of Honor” State Academy of Veterinary Medicine
- Vol. 60 (4)
Open AccessTOXICITY PARAMETERS OF A COMPLEX ANTIMICROBIAL DRUG BASED ON LEVOFLOXACIN USED ON WHITE MICE
The article presents the results of a study of the acute toxicity of a new antimicrobial drug based on levofloxacin. The trial was conducted on white laboratory mice, which were administered the drug under investigation once at different doses intragastrically and subcutaneously. As a result of the study, toxicity parameters were established, which made it possible to classify the new drug as Hazard class 4. The LD50 for subcutaneous administration for white mice was 13126.57±1537.49 mg/kg.